Factitious hypoglycemia in insulin-treated diabetic patients

Area of Science:

• Endocrinology
• Psychiatry
• Clinical Diagnostics

Background:

• Factitious hypoglycemia is a factitious disorder (DSM-5) involving intentionally induced low blood sugar, with potentially severe health outcomes.
• Current understanding relies on case reports, lacking evidence-based guidelines, making diagnosis difficult, especially in insulin-treated diabetic individuals.
• Traditional diagnostic markers (insulin levels, C-peptide) may be unreliable due to insulin analog interference with certain assays.

Purpose of the Study:

• To address the diagnostic challenges associated with factitious hypoglycemia in insulin-treated patients.
• To highlight the limitations of conventional diagnostic methods in differentiating factitious hypoglycemia from insulinoma.
• To present an emerging diagnostic strategy for suspected factitious hypoglycemia.

Main Methods:

• Review of existing literature and case reports on factitious hypoglycemia.
• Analysis of diagnostic metrics for differentiating factitious hypoglycemia from insulinoma.
• Evaluation of the utility of insulin quantification methods, particularly concerning insulin analogs.

Main Results:

• Diagnosing factitious hypoglycemia is often a prolonged and expensive process due to a lack of clear guidelines.
• Standard tests differentiating factitious hypoglycemia from insulinoma (high insulin/low C-peptide vs. high insulin/high C-peptide) are not universally applicable.
• The applicability of standard tests is compromised when insulin analogs interfere with insulin quantification assays.

Conclusions:

• Factitious hypoglycemia presents significant diagnostic hurdles, particularly in patients managed with insulin.
• Emerging evidence suggests combining two insulin quantification methods with differential cross-reactivity for insulin analogs early in diagnosis is beneficial.
• This combined approach may improve the accuracy and efficiency of diagnosing factitious hypoglycemia.